Trevi Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.72M, a 13138.46% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $222.00K, a 69.08% decline year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $225.00K, a 1630.77% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.12M, a 593.21% increase year-over-year.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $2.08M, a 427.66% increase from fiscal 2024.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $394.00K, a 432.43% increase from fiscal 2023.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $74.00K, a 46.76% decline from fiscal 2022.
- Trevi Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $139.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.72M 10-Q · filed 2026-08-06 | $3.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $222.00K 10-Q · filed 2026-05-05 | $1.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.08M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.12M 10-Q · filed 2025-11-13 | $1.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.00K 10-Q · filed 2026-08-06 | $906.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $718.00K 10-Q · filed 2026-05-05 | $1.11M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $394.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $162.00K 10-Q · filed 2025-11-13 | $381.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $214.00K 10-Q · filed 2025-08-07 | $222.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-08 | $15.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $74.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $3.00K 10-Q · filed 2024-11-06 | $72.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $7.00K 10-Q · filed 2024-08-08 | $208.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $62.00K 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $139.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $139.00K 10-Q · filed 2023-11-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $34.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $7.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $27.00K 10-Q · filed 2021-08-12 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $38.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $38.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $14.00K 10-Q · filed 2020-08-13 | $38.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $24.00K 10-Q · filed 2020-05-07 | $24.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $13.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | |
| 2018-03-31 | $13.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |